Trial Profile

A phase 2 pivotal, efficacy study of AVA6000 as a first line treatment in patients with soft tissue sarcoma

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 03 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AVA 6000 (Primary)
Indications Soft tissue sarcoma
Focus Registrational; Therapeutic Use

Most Recent Events

28 Sep 2023 According to an Avacta media release, this is potentially pivotal trial subject to receiving the necessary regulatory approvals. This trial is planned to start during 2024
22 Sep 2023 New trial record
20 Sep 2023 According to an Avacta media release, this study is expected to begin in Q4 2023 subject to receipt of approval of a protocol amendment from the US Food & Drug Administration (FDA).

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com